Research ArticleInflammation, Immunopharmacology, and Asthma
GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
Journal of Pharmacology and Experimental Therapeutics February 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743
Taruna Joshi
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Dong Yan
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Omar Hamed
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Stacey L. Tannheimer
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Gary B. Phillips
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Clifford D. Wright
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Musong Kim
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Michael Salmon
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Robert Newton
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
Mark A. Giembycz
Departments of Physiology and Pharmacology (T.J., D.Y., O.H., M.A.G.) and Cell Biology and Anatomy (R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Translational Medicine, Biomarkers (S.L.T.), Inflammation Research (C.D.W., M.S.), and Medicinal Chemistry (G.B.P., M.K.), Gilead Sciences Inc., Seattle, Washington
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleInflammation, Immunopharmacology, and Asthma
GS-5759, a Bifunctional LABA and PDE4 Inhibitor for COPD
Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
Journal of Pharmacology and Experimental Therapeutics February 1, 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743
Research ArticleInflammation, Immunopharmacology, and Asthma
GS-5759, a Bifunctional LABA and PDE4 Inhibitor for COPD
Taruna Joshi, Dong Yan, Omar Hamed, Stacey L. Tannheimer, Gary B. Phillips, Clifford D. Wright, Musong Kim, Michael Salmon, Robert Newton and Mark A. Giembycz
Journal of Pharmacology and Experimental Therapeutics February 1, 2017, 360 (2) 324-340; DOI: https://doi.org/10.1124/jpet.116.237743
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement